Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ADICON Holdings Limited ( (HK:9860) ) has issued an announcement.
ADICON Holdings Limited announced its interim results for the first half of 2025, reporting a revenue of RMB1.27 billion, a 13.3% decline from the previous year. Despite economic and policy challenges, the company showed resilience with growth in its co-construction and CRO businesses. The co-construction business grew by 30% year-on-year, driven by new hospital projects, while the CRO business increased by 18%, bolstered by partnerships in the diabetes field and innovations in solid tumor therapies.
The most recent analyst rating on (HK:9860) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on ADICON Holdings Limited stock, see the HK:9860 Stock Forecast page.
More about ADICON Holdings Limited
ADICON Holdings Limited is a leading independent clinical laboratory (ICL) service provider in China, offering comprehensive testing services primarily to hospitals and health check centers. The company operates an integrated network of 34 self-operated laboratories across China, with 24 accredited by ISO15189, and provides over 4,000 medical diagnostic tests, including high-end diagnostic tests and NGS assays.
Average Trading Volume: 2,226,175
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.71B
For detailed information about 9860 stock, go to TipRanks’ Stock Analysis page.